BioNexus Gene Lab Corp Common stock (BGLC) — Cash Flow Reinvestment Rate
BioNexus Gene Lab Corp Common stock (BGLC) has a Cash Flow Reinvestment Rate of 0.14x as of December 2022, reinvesting $66.93K (capex $17.03K plus investments $-49.90K) from operating cash flow of $474.47K. Check BioNexus Gene Lab Corp Common stock cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
BioNexus Gene Lab Corp Common stock Cash Flow Reinvestment Rate (2017–2022)
Historical reinvestment intensity for BioNexus Gene Lab Corp Common stock across 4 annual periods. Explore BioNexus Gene Lab Corp Common stock long-term investment intensity to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for BioNexus Gene Lab Corp Common stock (2017–2022)
Year-by-year capital reinvestment analysis for BioNexus Gene Lab Corp Common stock. For live market cap and broader valuation context, see BGLC stock market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 0.93x | $504.67K | $544.03K | $54.17K | ▼ -98.3% |
| 2021 | 55.96x | $512.61K | $9.16K | $3.16K | ▲ +6082.7% |
| 2020 | 0.91x | $500.19K | $552.68K | $421.62K | ▼ -1.1% |
| 2017 | 0.92x | $326.90K | $357.22K | $314.82K | — |